DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for oral submucous fibrosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOral submucous fibrosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oral submucous fibrosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A 2008 Cochrane review of interventions for oral submucous fibrosis identified only two randomised trials, involving 87 participants in total. One trial evaluated lycopene combined with intralesional steroid injections; the other tested pentoxifylline together with mouth stretching exercises and heat. The data from both trials were judged unreliable: one used inadequately defined outcome measures, the other had a substantial number of withdrawals that likely skewed the results. No toxicity was reported, but gastric irritation was noted with pentoxifylline. The review concluded that there was a paucity of reliable evidence for any specific intervention.
A 2021 clinical practice guideline noted that while many treatment protocols have been proposed, only a few are evidence-based. The guideline recommended topical interventions as first-line treatment because of their low risk of systemic side effects. It also stated that stopping areca nut use may have a considerable effect on symptoms but is unlikely to reverse pre-existing fibrosis. A 2023 case report of a 22-year-old Iranian man stated that no existing treatment can cure oral submucous fibrosis, and that some findings in that case differed from reference texts.
Two molecular reviews, from 2022 and 2025, examined the pathogenesis of oral submucous fibrosis. The 2022 review, covering 1990–2020, analysed 21 articles and concluded that transforming growth factor-beta may be a potential biomarker or target for therapy. The 2025 review, covering 2015–2025, included 12 articles and listed multiple proteins and genes implicated in the disease, including TGF-β, Wnt inhibitory factor-1, CypA, Hsp-70 1B, calreticulin, lumican, enolase 1, MMP-2, IGF-1R, XIST, epigallocatechin-3-gallate, von Hippel-Lindau, and MUC1 and 4. Both reviews emphasised that the molecular mechanisms remain poorly understood.
What is still missing is a reliable evidence base from adequately powered, well-designed randomised trials. No trial has yet demonstrated a reproducible, disease-modifying treatment. The molecular targets identified in genomic studies have not been translated into tested therapies. Patient stratification by disease stage or molecular subtype has not been attempted in a clinical trial. Funding for definitive trials and for translational work linking genomic findings to clinical outcomes remains insufficient.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cochrane Database of Systematic Reviews · 2008 · 42 citations
Interventions for the management of oral submucous fibrosis
AbstractBACKGROUND: Oral submucous fibrosis (OSF) is a chronic disease of the oral cavity which is more commonly found in patients in the Asian subcontinent and the Far East. It is characterised by the progressive build up of constricting bands of collagen in the cheeks and adjacent structures of the mouth which can severely restrict mouth opening and tongue movement and cause problems with speech and swallowing. OBJECTIVES: To assess the effectiveness of interventions for the management of pain and restricted jaw opening or movement occurring as a result of oral submucous fibrosis. SEARCH STRATEGY: We searched the Cochrane Oral Health Group's Trials Register to July 2008; CENTRAL (The Cochrane Library 2008, Issue 2); MEDLINE (from 1950 to July 2008); EMBASE (from 1980 to July 2008) and IndMED on 18th November 2007. There were no language restrictions. SELECTION CRITERIA: Randomised controlled trials comparing surgical interventions, systemic or topical medicines or other interventions to manage the symptoms of oral submucous fibrosis. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted trial data. Disagreements were resolved by consultation with a third author. Attempts were made to contact study authors where necessary for clarification and for additional information. MAIN RESULTS: Two trials, involving 87 participants, evaluated lycopene in conjunction with intralesional injections of a steroid, and pentoxifylline in combination with mouth stretching exercises and heat. Only two of the primary but none of the secondary outcomes of this review were considered in these trials and provided a limited amount of unreliable data. The data in one trial were based on inadequately defined evaluations of outcomes, and in the other trial are likely to be skewed due to a substantial number of withdrawals and therefore were not entered into the RevMan analyses. There were no reports of toxicity to the interventions but some side effects, which were mostly gastric irritation to pentoxifylline, were noted. AUTHORS' CONCLUSIONS: The lack of reliable evidence for the effectiveness of any specific interventions for the management of oral submucous fibrosis is illustrated by the paucity, and poor methodological quality, of trials retrieved for this review.
Journal of Oral and Maxillofacial Pathology · 2022 · 6 citations · open access
Leaving no stone unturned
AbstractIntroduction: Understanding the molecular pathogenesis of an entity helps in devising the mode of progression as well as mode of therapy. Even with years of research to claim the understanding of the molecular pathogenesis of oral submucous fibrosis (OSMF) is limited. More deeper knowledge of the genes responsible for this will help in understanding and managing this disease better. Materials and Methods: The articles published during a time period of 1990-2020 were chosen in accordance with the inclusion and exclusion criteria according to the PRISMA guidelines. Results: From a total of 80 articles obtained from both electronic search of PUBMED, EMBASE, MEDLINE and Cochrane registry as well as the manual search only 21 articles were selected and analyzed. Conclusion: Careful analysis of the samples revealed that transforming growth factor-beta may be a potential biomarker or a candidate for targeted therapy in OSMF.
International Journal of Dentistry and Oral Science · 2021 · 2 citations · open access
Clinical Practice Guidelines For Management Of Oral Submucous Fibrosis
AbstractBackground: Oral sub mucous fibrosis (OSMF) is a chronic, progressive, debilitating, scarring and crippling disorder of the oral cavity. It is characterized by inflammation, increased deposition of sub mucosal collagen and formation of fibrotic bands in the oral tissues, which increasingly limitmouth opening. Many OSMF treatment protocols have been proposed to alleviate the signs and symptoms of the disorder and there is overwhelming evidence that as areca nut is primary cause, stopping its use may have a considerable effect on symptoms rather than reversing pre-existing fibrosis. Even though several treatment modalities have been recommended, only a few are evidence based and can be considered for the optimal management of oral sub mucous fibrosis. The objective of this study was to propose and review treatment protocol to be followed for the management of oral sub mucous fibrosis. We reviewed several evidence-based studies and through this review we recommend topical interventions as the first-line of treatment since they are associated with low risk of systemic side effects.
Molecular Genomics of Oral Submucous Fibrosis: A Narrative Review
AbstractBACKGROUND: Oral Submucous Fibrosis (OSMF) is a chronic, progressive condition characterized by the fibrosis of the oral mucosa, often associated with the habitual consumption of areca nut and tobacco, leading to significant morbidity. Despite its prevalent occurrence in many parts of the world, the underlying genetic and molecular mechanisms remain poorly understood, highlighting a critical need for research into its molecular genomics. The aim of this literature review is to investigate the molecular genomics of Oral Submucous Fibrosis by analyzing the relevant literature of the past decade. METHODS: The search was conducted using MEDLINE (National Library of Medicine)-PubMed, focusing on the period 2015-2025 using the following keywords: Molecular Genomics AND Oral Submucous Fibrosis. This was followed by a manual search, and references were used to identify relevant articles. RESULTS: A total of 12 articles were included in our review according to our inclusion criteria, which illustrated the importance of TGF-β, Wnt inhibitory factor-1, CypA, Hsp-70 1B, Calreticulin, Lumican, Enolase 1, MMP-2, IGF-1R, XIST, Epigallocatechin-3-gallate, Von Hippel-Lindau, and MUC1 and 4. CONCLUSIONS: Understanding the molecular pathogenesis of OSMF involves examining the molecular interactions and the roles of specific proteins. Advanced genomic technologies have opened new frontiers in the study of OSMF. As research in OSMF continues to evolve, emerging interdisciplinary approaches may provide therapeutic strategies, aiming to improve management outcomes for the patients.
WORLD JOURNAL OF PLASTIC SURGERY · 2023 · 1 citations · open access
Oral Submucous Fibrosis: a Premalignant Condition in a 22-Year-Old Iranian Man
AbstractOral submucous fibrosis (OSF) is a chronic, irreversible disease. The etiology of OSF has been linked to several risk factors, including local factors, systemic factors, and immunological disorders. We report a 22-year-young male patient case of Oral submucous fibrosis, referred to the Maxillofacial Surgery Department of Zahedan University of Medical Sciences, Zahedan, Iran. Treatment for oral submucous fibrosis is based on the disease's clinical involvement and rate of advancement. Even though there are numerous innovative therapeutic techniques for this illness, none of them can cure it. Early diagnosis and treatment can improve the quality of life of a person. Some of the findings of this study are different from reference texts and other studies.
International Journal of Research and Review · 2022 · 0 citations · open access
2 Layered Closure by Buccal Fat Pad and Collagen Sheath in Severe OSMF: A Case Report
AbstractOral Submucous fibrosis is a disease common among developing countries of South-east Asia. The condition was first demonstrated by Schwartz in 1952, and Pindborg et al have done extensive research to explain the pathophysiology of the disease. This potentially malignant condition once initiated cannot be reversed completely and the long standing cases suffer from altered nutrition status, poor intraoral hygiene and disarticulation. Hence, this disease should be dealt with radical surgical intervention and reconstruction with the appropriate method to prevent recurrence and increase the quality of life for the patients. Keywords: Oral Submucous fibrosis, Potentially malignant condition, Reconstruction
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
